Sumitomo Pharma Co., Ltd.

Sumitomo Dainippon Pharma Co., Ltd.

Boston Biomedical, Inc.

Sumitomo Dainippon Pharma Oncology, Inc.

Wataru Hirose

Naoaki Shimada

Hitoshi Ban

Seiji Kamioka

Akihiko Arakawa

Kazuto Yamazaki

Kenjiro Hira

Chiang Jia Li

Wei Li

David Leggett

Hiroki Umehara

Toshihiko Sone

Kento Hayashi

Makoto Matsuoka

Adam Siddiqui-Jain

Yusuke Sawayama

Akihiko Yokoyama

The present disclosure provides a compound that exerts an anticancer action based on CHK1 inhibition. The present disclosure was completed by finding that a compound represented by formula (1) or a pharmaceutically acceptable salt thereof exhibits an excellent antitumor action by having a potent inhibitory action against CHK1: wherein R, R, L, V, W, and Q are as defined herein, X, Y, and Z each independently represent CRor a nitrogen atom, wherein X, Y, and Z are not simultaneously CR, and Ris as defined herein.

5-heteroaryl-1H-pyrazol-3-amine derivative

The compound of formula (1a) wherein p is 1 or 2, R-Rare hydrogen atom or the like, and a-d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.

Optically active azabicyclo ring derivative

The present invention relates to the compound of formula (1a) wherein p is 1 or 2, R-Rare hydrogen atom or the like, and a-d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin. 

The present invention relates to the compound of formula (I) wherein p is 1 or 2, Ris &#x2014;CFor the like, R, R, R, and Rare hydrogen atom or the like, X is &#x2014;C(&#x2550;O)&#x2014;or the like, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin. 

Optically active crosslinked cyclic secondary amine derivative

Compounds having the following structure (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R, Rand Rare as defined herein, and wherein at least one of R, Rand Ris not H, are provided. Pharmaceutical compositions comprising the compounds and methods for use of the compounds for treating diseases associated with overexpression of a cyclin-dependent kinase (CDK) are also provided. 

Alvocidib prodrugs and their use as protein kinase inhibitors

The present invention provides a compound of the following Formula (1) or a pharmaceutically acceptable salt thereof: wherein X is an oxygen atom and the like; Y is &#x2014;CO&#x2014;, &#x2014;SO&#x2014; and the like; Ris an optionally-substituted Calkyl group, an optionally-substituted Calkylcarbonyl group and the like; Ris an optionally-substituted Calkyl group, an optionally-substituted Calkoxy group, an optionally-substituted amino group, an optionally-substituted 5- to 12-membered monocyclic or polycyclic saturated heterocyclic group and the like; R, R, R, and Rare independently a hydrogen atom and the like which exhibits excellent effects in suppressing the proliferation and sphere-forming ability of cancer cells, and can be useful as an antitumor drug or cell growth inhibitor.

3-substituted carbonyl-naphtho[2,3-B]furane derivative or pharmaceutically acceptable salt thereof

Growing community of inventors

Osaka, Japan

Wataru Hirose